HOFFMAN ESTATES, Ill.--(BUSINESS WIRE)--Siemens Medical Solutions (www.usa.siemens.com/medical) announced that it has been granted an Investigational New Drug (IND) Exemption by the U.S. Food and Drug Administration (FDA) to conduct a Phase I clinical trial of [F-18] 3'-fluoro-3'-deoxythymidine (FLT), a molecular imaging biomarker that has shown promise in monitoring the proliferation of cancer cells, which could help physicians quickly determine the effectiveness of cancer therapies.
To broaden the scope of FLT research, Siemens will support the FLT Phase I clinical trial that will be conducted at Memorial Sloan-Kettering Cancer Center located in New York City, with whom Siemens has signed a research collaboration agreement focused on the codevelopment of imaging biomarkers that will be used in PET imaging. Through these collaborative efforts, Siemens intends not only to make FLT more readily accessible to research and academic institutions for further study, but also to continue research into new more target specific imaging biomarkers for PET.
